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Abstract
A patient with aplastic anaemia, successively treated with caspo-
fungin then liposomal amphotericin, developed a disseminated
infection due to Acremonium, further confirmed as resistant in vitro
to these drugs. Successful treatment was achieved with voriconaz-
ole. Multiple antifungal treatments may expose to the risk of
breakthrough of multi-resistant pathogens in haematology patients.
Keywords: Acremonium, amphotericin B resistance, caspofungin
resistance, opportunistic infections, severe aplastic anaemia
Original Submission: 27 March 2013; Revised Submission: 6
June 2013; Accepted: 27 June 2013
Editor: M. Drancourt
Article published online: 2 July 2013
Clin Microbiol Infect 2014; 20: O30–O32
10.1111/1469-0691.12319
Corresponding author: J. Guitard, laboratoire de Parasitologie
Mycologie, Ho^pital St Antoine, 184 rue du faubourg St Antoine, 75012
Paris, France
E-mail: juliette.guitard@sat.aphp.fr
*These two authors have equally participated in this work.
Introduction
A 25-year-old male native of French Polynesia was diagnosed
in January 2011 with severe idiopathic bone marrow aplasia.
Working as an employee in naval construction, the patient was
used to manipulating chlorhydric acid, dye stuffs and solvents.
When admitted to our institution, the patient was febrile at
39.5°C. Complete blood count revealed leucocytes at 1.21 G/
L. Initial antibiotic therapy consisted of piperacillin–tazobactam
plus gentamycin. In the absence of a genotypically matched
donor, the patient started at Day 0 (D0) a 3-month course of
immunosuppressive treatment combining anti-thymocytic
globulin, cyclosporin and methylprednisolone followed by
granulocyte–colony-stimulating factor administration for
70 days. As fever persisted, antibiotic treatment was changed
at D6 leading to apyrexia within 24 h. However, a blood
culture sampled at D12 because of the re-emergence of the
fever, returned positive for yeasts, further identified as Candida
metapsilosis. Liposomal amphotericin B at 3 mg/kg/day was
added, and produced a rapid recovery from the fever.
However, this resulted in renal function impairment (blood
creatinine at 130 mg/dL), which forced, at D20, a switch to
caspofungin (50 mg/day after a loading dose of 70 mg). On
D41, while the patient was still neutropenic (leucocytes at
0.08 G/L), multiple cutaneous lesions appeared on his back,
trunk and all extremities, but sparing his palms and soles. They
were well-circumscribed, non-blanching, non-purpuric,
non-pruritic, erythematous nodules, approximately 8–14 mm
in diameter. Pathological examination of these nodules showed
dermal, epidermal and vascular fungal infiltration, with
blood-vessel fungal thrombosis. Periodic acid-Schiff staining
revealed thin septate hyaline hyphae and cultures grew with a
filamentous fungus suggestive of Acremonium. At the same time,
the patient complained of pain of the right great toenail, which
appeared with an inflammatory partial onycholysis. Direct
examination of the nail scrapping demonstrated the presence
of thin septate hyaline hyphae with a positive culture for
Acremonium. Similarly, a blood culture sampled on D42 grew
positive for Acremonium. Total body computed tomography
(CT) scan revealed micro-hypodensities disseminated in the
lung fields but no further bronchopulmonary investigation was
performed. Serological galactomannan antigen (BioRad, Her-
cules, CA, USA) assayed twice a week remained negative.
Caspofungin was changed for oral voriconazole (5 mg/kg twice
a day). From then, the cutaneous lesions progressively healed,
the patient became apyretic and systematic blood cultures
remained negative. The patient was discharged 3 months later
while a CT scan demonstrated the disappearance of the chest
nodules. Oral voriconazole was continued for 6 months.
Neutrophil count only returned to normal at D77.
Acremonium isolates were tested for their in vitro antifungal
susceptibility using the Etest method (BioMerieux, Marcy
l’Etoile, France ), according to the manufacturer’s recommen-
dations. The MIC of amphotericin B, fluconazole, itraconazole,
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voriconazole, caspofungin and 5-fluorocytosine were 12, >256,
1.5, 0.125, >32 and >32 mg/L, respectively. The in vitro
resistance was confirmed using a conventional microdilution
assay (CLSI methodology) showing MICs of amphotericin B,
itraconazole, voriconazole and posaconazole at 2, >8, 1 and
1 mg/L, respectively. This strain is now included in the CBS
collection (CBS135846; CBS-KNAW Fungal Biodiversity Cen-
tre, Utrecht, the Netherlands).
Aspergillus and Candida remain the leading cause of invasive
fungal infections in haematology patients [1,2]. However, during
the last decades unusual pathogens, such as zygomycetes or
Fusarium, have emerged in these populations and cause difficul-
ties in diagnosis and therapeutic management because of their
reduced susceptibility to different classes of antifungal drugs.
Acremonium spp. are common soil and plant saprophytes but
can be the aetiological agent of superficial infections such as
onychomycosis [3], and more rarely invasive infections [4–6].
Haematological patients, particularly allogeneic haematopoietic
stem cell transplant or acute leukaemia patients, are the most
frequently involved [1,2] but, to our knowledge, we report the
first case occurring in a patient suffering severe aplastic
anaemia. The characteristics of disseminated Acremonium
infection are very similar to those of Fusarium infections [7].
The triad skin lesions–pneumonia–blood culture positive for a
filamentous fungus in a patient with adapted antibiotic therapy
suggests the diagnosis of infection with either Fusarium or
Acremonium [5]. In our case, the pulmonary involvement could
not be documented but is likely considering the favourable
outcome of the lesions that were visible on CT scans when
appropriate antifungal therapy was initiated. As already
reported for Fusarium infection [8], onychomycosis may have
been the starting point of dissemination and, it must be
remembered that nails should be systematically examined
before the initiation of cytotoxic chemotherapy.
The taxonomy of Acremonium has been reviewed in depth
and supports the need for a molecular approach for definitive
identification [9]. The internal transcribed spacer sequence of
our strain, (accession number KF156781), was identical to the
AY138844 sequence in GenBank, deposited as Acremonium
strictum (strain UW836). However, the revision of the
taxonomy considered this strain as belonging to the Acremo-
nium sclerotigenum- Acremonium egyptiacum group (group P), as
does our strain and the majority of clinical isolates tested in
this study, with the possible exception of mycetoma [9].
There is little information regarding the susceptibility of
Acremonium species to antifungals, but they are characteristi-
cally resistant to the anti-Candida agents, fluconazole and
flucytosine. Although there is a lack of breakpoint data for
those organisms, MICs against amphotericin B are commonly
elevated, which suggests poor activity of this drug. Acremonium
sclerotigenum-A. egyptiacum group seems to be less susceptible
to amphotericin B [9], as supported by our results showing an
amphotericin B MIC at 12 mg/L and 2 mg/L using the Etest and
the CLSI method, respectively, of which the latter has been
shown to be less sensitive than Etest for detection of
resistance to amphotericin B at least in Candida [10].
Finally, posaconazole and voriconazole may be the best
therapeutic alternative. The clinical history of our patient
correlated with these in vitro peculiarities: breakthrough of the
Acremonium infection while the patient had been treated with
liposomal amphotericin B and was receiving caspofungin and
favourable outcome using a prolonged course of voriconazole.
However, it should be mentioned that this outcome also
correlates with the progressive recovery of a normal neutro-
phil count, which remains an essential prognosis factor of
invasive fungal infection. With the wider use of anti-Candida
agents and liposomal amphotericin B, clinicians must be aware
of the list of fungal pathogens resistant to these drugs among
which Trichosporon spp. [11], Aspergillus ustus [12] and Acremo-
nium spp. are predominant.
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